Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims


     Quick Explanation



    Author review (brief)

    Ramaswamy Govindan is a highly-cited lung‑cancer and oncology researcher with several high‑impact, widely‑cited papers (Cell, Nature, JCO, NEJM) and extensive co‑authorship on large consortia; however, author identity/metric sources vary and should be reconciled before decision‑critical use. Key representative works are cited below.

    See long review for visual metrics, caveats, and reproducible evidence.




     Long Explanation



    Author Review: Ramaswamy Govindan — Visual & Evidence‑first

    Representative metrics (visualized papers / findings)

    Data source: SEER analysis extracted in the supplied research data (percentages shown are taken directly from the SEER study extraction provided by the user) — see citation below for the SEER‑based analysis.

    Citation and authorship evidence (representative high‑impact works)

    Govindan appears as first/senior coauthor on several high‑impact, widely‑cited works in lung cancer and cancer genomics (examples below):

    • Cell 2012 — Genomic landscape of NSCLC (first author Govindan) — demonstrates leadership in genomics and translational cancer research and remains highly cited (doi:10.1016/j.cell.2012.08.024).
    • Journal of Clinical Oncology 2006 — SCLC epidemiology (first author Govindan) — large SEER analysis (doi:10.1200/JCO.2005.04.4859).
    • Coauthor on high-profile translational and clinical guideline papers (e.g., Lancet 2020 Sex & Gender review; Govindan is a middle coauthor) showing multidisciplinary collaboration.

    These papers indicate strong domain expertise in lung cancer, translational genomics, and clinical epidemiology.

    Note: there are two sets of author‑level metrics in the materials supplied (a small-profile 'R. Govindan' and an OpenAlex record for 'Ramaswamy Govindan' with large metrics). These are probably different disambiguated author records or reflect full-author vs partial-author name forms — reconcile before relying on raw h-index numbers for evaluation.

    Representative observed discrepancies:

    • Provided short author list/metrics: h-index 11, 575 citations, 55 papers (small profile).
    • OpenAlex top author snapshot: works_count ~1205, cited_by_count ~96,359, h_index ~127 (very large, multi-decade corpus) — likely a different or aggregated profile (requires identity disambiguation).

    Consequences: using an incorrect author record will either under- or over-estimate influence; always verify via ORCID / institutional profile / PubMed author identifier.

    Critical strengths

    • High‑impact publications (Cell, JCO, contributions to NEJM and Lancet reviews) indicate strong scientific influence and collaborative leadership in lung cancer genomics and clinical oncology.
    • Work spans epidemiology, genomics, clinical trials, and translational pathology — breadth supports robustness and translational relevance.
    • Frequent coauthorship on large consortia and resource papers suggests access to large datasets and reproducible workflows (good for translation and replication).

    Potential weaknesses, blindspots, and caveats

    • Author identity disambiguation: conflicting metric sets (small profile vs OpenAlex aggregated profile) risk mis-evaluation — verify ORCID and institutional affiliation (the OpenAlex entry lists ORCID: https://orcid.org/0000-0002-6964-9612) before metrics-driven decisions.
    • Many multi‑author consortia papers make it hard to parse individual intellectual contributions from large team outputs — assess contribution statements where available.
    • Older cohort or registry studies (e.g., SEER 1988–2003) may be limited by missing confounders (smoking, comorbidities) and changes in diagnostic/therapeutic standards — interpret effect sizes accordingly.
    • Possible citation / publication bias: highly cited methodological/consortium papers can inflate h-index without reflecting independent hypothesis-driven contributions; check first/last authorship and contribution sections.

    What would change this assessment?

    • If ORCID/institutional profile confirms the high OpenAlex metrics and shows consistent first/senior authorship across many high‑impact papers, confidence increases substantially.
    • If disambiguation shows that the large OpenAlex profile combines multiple distinct R. Govindan authors, the true per-person influence may be much lower — confidence decreases.


    Feedback:    

    Updated: March 18, 2026

     BGPT Author Review



    Scientific Quality

    80%

    Evidence shows leadership in lung cancer genomics and epidemiology with multiple high-impact, well-cited consortium and first‑author papers; score reduced from a maximal value because (1) authorship disambiguation issues exist across data sources and (2) many outputs are multi‑author consortia making individual contribution uncertain.



    Communication Quality

    80%

    Papers are published in clear, reputable journals with accessible methods and data summaries; many clinical and translational outputs indicate effective communication to both research and clinical audiences; slight deduction for variable availability of explicit contribution statements in multi-author works.



    Author Novelty

    70%

    Contributions include important integrative genomic and epidemiologic findings (e.g., Cell 2012 NSCLC landscape) that materially advanced understanding of lung cancer biology; novelty is solid but often within collaborative large-consortium frameworks rather than lone-groundbreaking theory.



    Scientific Rigor

    80%

    Methods across representative papers (large cohorts, multi-omic integration, SEER epidemiology, clinical trials) show appropriate statistical and experimental rigor; some registry-based studies are limited by missing covariates (smoking/comorbidity) which lowers universal rigor slightly.

     Analysis Wizard



    Preparing an automated pipeline to (1) match publications to ORCID/institution, (2) fetch contribution statements and first/last authorship, and (3) compute field-normalized citation metrics using supplied DOIs and OpenAlex IDs.



     Science Art


    Author Review: Ramaswamy Govindan Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT